Impacting society, creating change
Technologies developed at Ohio State are changing the world. Learn more about the startups that are currently a part of the Ohio State portfolio or download our printable catalog (as of June 30, 2019).
Search for a Startup below
AccuFiber Technologies electrospins core-shell, nanofiber-based, oxygen sensors and targets commercially viable products based on this technology. Compared to conventional or optical-based sensors, the company’s nanofiber-based sensors have several advantages including greater sensitivity, lower manufacturing costs and real-time detection of even low levels of oxygen. The company is integrating its nanofiber-based oxygen sensor into a wide range of products, with initial efforts focused on military applications.
RNA‐Seq provides comprehensive transcriptome profiling and allows for both mapping and quantifying transcriptome signatures associated with diseases.
Spirosure is developing devices using novel, breath-based analysis technology to diagnose and manage respiratory diseases. The company's breath-analysis devices focus on providing cost-effective, non-invasive products to diagnose and manage chronic respiratory disease, such as asthma, COPD and chronic pulmonary hypertension. The company uses novel sensors, proprietary algorithms and consumer technology, enabling medical researchers to detect biomarkers in a patient's breath to diagnose and monitor respiratory conditions.
SpineDynX is a medical device company commercializing the clinical lumbar motion monitor (cLMM). The cLMM enables improved outcomes for spine treatment at the point of care by providing objective and actionable data. Currently, there is a lack of objective data to accurately diagnose, track and treat low back pain. The cLMM uses an extensive patient database to assess a patient’s back in motion and accurately determine the extent and nature of impairment, as well as current re-injury risk.
S4 Medical is a medical device company focused on innovative solutions for cardiac procedures to treat atrial fibrillation (Afib). Afib is an irregular heartbeat affecting 30 million people worldwide. Catheter ablation is an effective treatment for Afib, but carries a risk of esophageal injury due to the close anatomical position of the heart and esophagus. The company’s initial product is a simple, yet comprehensive, solution for reducing complications to the esophagus during catheter ablation treatment for Afib, resulting in improved patient outcomes.